2017 American Society of Clinical Oncology Annual Meeting*

Download All
June 2-6, 2017; Chicago, Illinois
John M. Burke, MD; Elias Jabbour, MD; Rami S. Komrokji, MD; and Shaji Kumar, MD, review and share their expert perspectives on key hematologic malignancy findings presented at the 2017 American Society of Clinical Oncology Annual Meeting.
John M. Burke, MD
Sagar Lonial, MD
Farhad Ravandi, MD

Hematologic Malignancies

Momelotinib achieved noninferior spleen response vs rituximab, with inferior total symptom response rate.

Released: June 9, 2017

Results from this phase III study reveal comparable splenic response rate but improved symptomatic response and transfusion independence rates with momelotinib vs BAT.

Released: June 9, 2017

Study investigators conclude that molecular response may predict durable clinical benefit in patients treated with gilteritinib.

Released: June 14, 2017

Enasidenib was associated with durable CRs and low rates of treatment-related grade 3/4 adverse events.

Released: June 12, 2017

Results of 19-28z CAR T-cell treatment in patients with R/R B-cell ALL suggest higher CR rate, extended survival, and reduced toxicity in patients with baseline minimal vs morphologic disease burden.

Released: June 12, 2017

BR associated with significantly increased 5-year PFS, duration of response, and event-free survival vs R-CHOP/R-CVP in overall patient population, particularly in MCL subgroup.

Released: June 5, 2017

Rituximab plus lenalidomide showed activity, tolerable safety in patients with R/R follicular lymphoma, including those with double-refractory disease or early relapse on prior therapy.

Released: June 7, 2017

The addition of ublituximab to ibrutinib improved ORR vs ibrutinib alone with a similar safety profile except for an increase in ublituximab-related infusion reactions.

Released: June 6, 2017

Results from this interim analysis suggest no benefit to radiotherapy in elderly DLBCL patients who are PET negative for bulky disease after immunochemotherapy.

Released: June 8, 2017

Daratumumab addition to standard therapy was associated with an ORR of 100% after median follow-up of 10.8 months.

Released: June 6, 2017

Addition of elotuzumab to RVD associated with high level of overall response in newly diagnosed patients with MM but higher than expected toxicity.

Released: June 7, 2017

KCd use was associated with a lower rate of nonhematologic AEs and improved odds for PBSC mobilization vs KRd use.

Released: June 7, 2017

Results of this large international phase III trial showed that denosumab was associated with significantly less renal toxicity and prolonged PFS vs zoledronic acid in patients with newly diagnosed MM.

Released: June 14, 2017

Phase I results suggest isatuximab-based combination safe, clinically active in highly treatment-experienced R/R MM.

Released: June 8, 2017

In this expert analysis, Sagar Lonial, MD; John M. Burke, MD; and Farhad Ravandi, MD, review key data from the most clinically relevant studies on the management of hematologic malignancies presented at the 2017 Clinical Oncology annual meeting in Chicago.

John M. Burke, MD Sagar Lonial, MD Farhad Ravandi, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: August 18, 2017 Expired: No longer available for credit
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue